Cargando…

Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma

BACKGROUND: Transarterial chemoembolisation is the standard of care for intermediate stage (BCLC B) hepatocellular carcinoma, but it is challenging to decide when to repeat or stop treatment. Here we performed the first external validation of the SNACOR (tumour Size and Number, baseline Alpha-fetopr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mähringer-Kunz, Aline, Weinmann, Arndt, Schmidtmann, Irene, Koch, Sandra, Schotten, Sebastian, Pinto dos Santos, Daniel, Pitton, Michael Bernhard, Dueber, Christoph, Galle, Peter Robert, Kloeckner, Roman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923193/ https://www.ncbi.nlm.nih.gov/pubmed/29703174 http://dx.doi.org/10.1186/s12885-018-4407-5

Ejemplares similares

Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
por: Kloeckner, Roman, et al.
Publicado: (2015)

Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index
por: Müller, Lukas, et al.
Publicado: (2021)

Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?
por: Müller, Lukas, et al.
Publicado: (2021)

Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
por: Müller, Lukas, et al.
Publicado: (2021)

The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study
por: Mähringer-Kunz, Aline, et al.
Publicado: (2021)

Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance
por: Mähringer‐Kunz, Aline, et al.
Publicado: (2021)

Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma
por: Pitton, Michael B., et al.
Publicado: (2014)

Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function
por: Müller, Lukas, et al.
Publicado: (2021)

Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial
por: Kloeckner, Roman, et al.
Publicado: (2014)

Distant Metastases in Patients with Intrahepatic Cholangiocarcinoma: Does Location Matter? A Retrospective Analysis of 370 Patients
por: Hahn, Felix, et al.
Publicado: (2020)

Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort
por: Huber, Yvonne, et al.
Publicado: (2018)

Radiomics-Based Prediction of Future Portal Vein Tumor Infiltration in Patients with HCC—A Proof-of-Concept Study
por: Stoehr, Fabian, et al.
Publicado: (2022)

Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide
por: Müller, Lukas, et al.
Publicado: (2021)

Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC)
por: Perfahl, H., et al.
Publicado: (2020)

Survival prediction for patients with non-resectable intrahepatic cholangiocarcinoma undergoing chemotherapy: a retrospective analysis comparing the tumor marker CA 19-9 with cross-sectional imaging
por: Hahn, Felix, et al.
Publicado: (2020)

Risk prediction in intrahepatic cholangiocarcinoma: Direct comparison of the MEGNA score and the 8(th) edition of the UICC/AJCC Cancer staging system
por: Hahn, Felix, et al.
Publicado: (2020)

The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma
por: Gairing, Simon Johannes, et al.
Publicado: (2021)

Identifying optimal candidates for liver resection or transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma
por: Zhao, Shoujie, et al.
Publicado: (2020)

Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation
por: Mishra, Gauri, et al.
Publicado: (2020)

Risk Stratification in Advanced Biliary Tract Cancer: Validation of the A.L.A.N. Score
por: Müller, Lukas, et al.
Publicado: (2020)

Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: Lawson, Alexander, et al.
Publicado: (2023)

Efficacy of Transarterial Chemoembolisation with or without Antiviral Therapy for Patients with Hepatocellular Carcinoma after Radical Hepatectomy
por: Zhu, Yin, et al.
Publicado: (2018)

Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC
por: Müller, Lukas, et al.
Publicado: (2022)

(13)C-Methacetin Breath Test Predicts Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
por: Gairing, Simon Johannes, et al.
Publicado: (2022)

Prediction of postembolization syndrome after transarterial chemoembolization of hepatocellular carcinoma and its impact on prognosis
por: Roehlen, Natascha, et al.
Publicado: (2023)

Hypofractionated Stereotactic Radiotherapy after Transarterial Chemoembolisation Failure in an Unresectable Hepatocellular Carcinoma: A Case Presentation
por: Fiorica, Francesco, et al.
Publicado: (2013)

Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study
por: Tong, Huan, et al.
Publicado: (2017)

Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China
por: Li, Wei, et al.
Publicado: (2023)

Liver resection versus transarterial chemoembolisation for the treatment of intermediate hepatocellular carcinoma: a systematic review and meta-analysis
por: Bogdanovic, Aleksandar, et al.
Publicado: (2023)

A retrospective pilot study of transarterial chemoembolisation using camrelizumab-eluting Callisphere beads for unresectable hepatocellular carcinoma
por: Shi, Xiaonan, et al.
Publicado: (2023)

Transjugular Portosystemic Stent Shunt: Impact of Right Atrial Pressure on Portal Venous Hemodynamics Within the First Week
por: Pitton, Michael Bernhard, et al.
Publicado: (2021)

Elderly Patients with Hepatocellular Carcinoma Benefit from Liver Transplantation as Much as Younger Ones
por: Mittler, Jens, et al.
Publicado: (2022)

The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis
por: Cheng, Zhoujing, et al.
Publicado: (2020)

Postoperative adjuvant transarterial chemoembolisation improves survival of hepatocellular carcinoma patients with microvascular invasion: A multicenter retrospective cohort
por: Luo, Laihui, et al.
Publicado: (2023)

High pretreatment static and dynamic alpha‐fetoprotein values predict reduced overall survival in hepatocellular carcinoma
por: Czauderna, Carolin, et al.
Publicado: (2021)

Transarterial chemoembolisation for palliative treatment of renal cell carcinoma in two dogs with pulmonary metastasis
por: Kimata, A., et al.
Publicado: (2022)

Is Chemoembolisation of Value in Inoperable Primary Hepatocellular Carcinoma
por: Raoul, Jean-Luc
Publicado: (1998)

Survival Prediction in Intrahepatic Cholangiocarcinoma: A Proof of Concept Study Using Artificial Intelligence for Risk Assessment
por: Müller, Lukas, et al.
Publicado: (2021)

Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?
por: Müller, Lukas, et al.
Publicado: (2022)

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u033crao5igp0ua95t2fstveem